| Document |
Document Title |
|
WO/2000/063179A1 |
Neurotrophin potentiators which contain 6(5H)-phenanthridinone derivatives of general formula (I) or pharmacologically acceptable salts thereof and are useful as preventive or therapeutic drugs for nerve degeneration diseases: wherein R1...
|
|
WO2000004012A9 |
This invention is directed towards a method of inhibiting activation of a human alpha 1d adrenergic receptor which comprises contacting the receptor with a compound so as to inhibit activation of the receptor, wherein the compound binds ...
|
|
WO/2000/061587A1 |
The invention relates to novel pyrido-thieno-diazepines of general formula (I), wherein R¿1?, R¿2?, X, R¿3a?, R¿3b?, R¿4? represent various radicals, and to a method for the production thereof and to pharmaceutical compositions cont...
|
|
WO/2000/058406A1 |
A set of 4,7-dichlororhodamine compounds useful as fluorescent dyes are disclosed having the structures (I) and (VI) wherein R¿1?-R¿6? are hydrogen, fluorine, chlorine, lower alkyl, lower alkene, lower alkyne, sulfonate, sulfone, amino...
|
|
WO/2000/055118A1 |
The present invention discloses novel nuclear receptor ligands of formula (IA) or (IB). These compounds are useful for arylating a cysteine in a nuclear receptor.
|
|
WO/2000/053608A1 |
The invention concerns compounds of general formula (I) wherein: R¿1? represents a hydrogen atom, an alkyl, phenylalkyl, phenylhydroxyalkyl, furanylalkyl or furanylhydroxyalkyl group; R¿2? represents either a hydrogen or a halogen atom...
|
|
WO/2000/051986A1 |
Compounds of formula (I) are useful in treating diseases prevented by or ameliorated with potassium channel openers. Also disclosed are potassium channel opening compositions and a method of opening potassium channels in a mammal.
|
|
WO/2000/052099A1 |
Perylene-3,4-dicarboximides of Formula (I) wherein R¿1? may be C¿1?-C¿20?alkyl, C¿3?-C¿14?cycloalkyl, C¿1?-C¿20?alkoxy, phenyl, phenyloxy or phenylthio, where phenyl may in each case be mono- or polysubstituted by halogen, C¿1?-C...
|
|
WO/2000/050397A1 |
Piperidinedione derivatives represented by general formula (1) (wherein R?1¿ and R?2¿ each represents halogeno, C¿1-6? alkyl, C¿1-6? alkylsulfonyl, etc.; R?3¿ represents halogeno, C¿1-6? alkyl, etc.; n is 0, 1, or 2; R?4¿ and R?5Â...
|
|
WO/2000/048999A1 |
Medicinal compositions having an effect of regulating the activation of glycine receptor and novel morphan derivatives. Medicinal compositions comprising morphan derivatives or its salts and a pharmaceutically acceptable carrier. These c...
|
|
WO/2000/047571A1 |
A compound of formula (I) wherein X is (II) or (III) wherein R' is a group (a), R is a group (e) or (f) wherein n is 0 to 3. In particular the agents of the invention inhibit the formation of $g(b)-amyloid (A$g(b)) peptide into neurotoxi...
|
|
WO/2000/047562A1 |
The present invention relates compounds of formula (I): wherein R?1¿, R?2¿, R?3¿, R?4¿ and R?5¿ represent a variety of substituents; R?6¿ represents hydrogen, COR?a¿, CO¿2?R?a¿, COCONR?a¿R?b¿, COCO¿2?R?a¿, C¿1-6?alkyl optio...
|
|
WO1999063936A9 |
Novel multi-binding compounds (agents) which bind endothelin receptors are used to treat disorders affecting the cardiovascular, renal, endocrine and nervous systems in mammals that are mediated by the endothelin receptors, such as conge...
|
|
WO/2000/046205A1 |
This invention relates to colorants comprising naphthalimide base groups with specific water-solubilizing pendant moieties attached. These pendant moieties are based upon aryloxy-poly(oxyalkylene) groups which provide the desired solubil...
|
|
WO1999066944A9 |
Disclosed are novel multi-binding compounds (agents) which bind cellular receptors. The compounds of this invention comprise a plurality of ligands each of which can bind to such cellular receptors thereby modulating the biological proce...
|
|
WO/2000/042040A1 |
Compounds of formula (I) are poly(ADP-ribosyl)transferase (PARP) inhibitors, and are useful as therapeutics in treatment of cancers and the amelioration of the effects of stroke, head trauma, and neurodegenerative disease. As cancer ther...
|
|
WO/2000/042018A1 |
Compounds of formula (I), in which R1, R2, R3, R31, R4, R5, R51 and R6 have the meanings indicated in the description, are novel active bronchial therapeutics.
|
|
WO/2000/042019A1 |
Compounds of formula (I), in which R1, R2, R3, R31, R4, R5, R51 and Ar have the meanings indicated in the description, are novel active bronchial therapeutics.
|
|
WO/2000/042017A1 |
The N-oxides of the compounds of formula (I), in which R1, R2, R3, R31, R4, R5, R51 and R6 have the meanings indicated in the description, are novel active bronchial therapeutics.
|
|
WO/2000/042020A1 |
Compounds of formula (I), in which R1, R2, R3, R31, R4, R5, R51, R6, R13 and R20 has the meanings indicated in the description, are novel active bronchial therapeutics.
|
|
WO1999064035A9 |
Disclosed are multibinding compounds which are beta 2-adrenergic receptor agonists and are useful in the treatment and prevention of respiratory diseases such as asthma, bronchitis. They are also useful in the treatment of nervous system...
|
|
WO/2000/039102A1 |
This invention relates generally to inhibitors of trypsin-like serine protease enzymes, especially factor Xa or thrombin, pharmaceutical compositions containing the same, and methods of using the same as anticoagulant agents for treatmen...
|
|
WO/2000/039108A1 |
This invention relates generally to inhibitors of trypsin-like serine protease enzymes, especially factor Xa or thrombin, pharmaceutical compositions containing the same, and methods of using the same as anticoagulant agents for treatmen...
|
|
WO/2000/038683A1 |
This invention relates generally to inhibitors of trypsin-like serine protease enzymes, especially factor Xa or thrombin, pharmaceutical compositions containing the same, and methods of using the same as anticoagulant agents for treatmen...
|
|
WO1999064034A9 |
The present invention is directed to multibinding compounds which are beta 2 adrenergic receptor agonists and are therefore useful in the treatment and prevention of respiratory diseases such as asthma, bronchitis, and the like. They are...
|
|
WO/2000/035457A1 |
A method of treating organic erectile dysfunction, particularly vasculogenic erectile dysfunction comprises administering to a male in need of such treatment a therapeutically effective amount of apomorphine or a pharmaceutically accepta...
|
|
WO/2000/034245A2 |
The present invention relates to pharmaceutical agents. More particularly, this invention relates to a novel crystalline form of an octahydro-benzo[f]quinolin-3-one derivative, to pharmaceutical formulations containing this crystalline f...
|
|
WO/2000/034237A2 |
Compounds of formula (I) wherein R¿1?-R¿5? are independently selected from hydrogen, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, perhaloalkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to ...
|
|
WO/2000/034246A1 |
The present invention relates to pharmaceutical agents. More particularly, this invention relates to a novel crystalline form of an octahydro-benzo[f]quinolin-3-one derivative, to pharmaceutical formulations containing this crystalline f...
|
|
WO/2000/032175A2 |
The invention provides pharmaceutical non-peptidic organic compounds capable of interacting with a functionally defective form of a mutant or a wild-type tumor suppressor protein of the p53 family (such as p53, p63 or p73). The interacti...
|
|
WO/2000/032577A2 |
Novel compounds of formula (I) in which R, R?1¿ and R?2¿ have the meaning indicated, and their salts or solvates as glycoprotein IbIX antagonists.
|
|
WO/2000/030589A2 |
A process for preparing a compound having formula (I) by (A) reacting a compound having formula (II), wherein R?5¿ is aryl or heteroaryl, with a dehydrating agent to produce an imine having formula (IIa); and (B) hydrolyzing the imine p...
|
|
WO/2000/031039A1 |
Novel compounds of formula (I), in which R, R?1¿, R?2¿ and i have the meaning indicated in Patent Claim 1, and their salts or solvates as glycoprotein IbIX antagonists.
|
|
WO/2000/029381A1 |
The invention relates to compounds of formula (I), to a method for producing them and to their use in medicaments as NOS inhibitors.
|
|
WO/2000/027845A1 |
Compounds of general structural formula (I) such as that shown in structural formula (II) are selective NPY Y5 receptor antagonists, useful in the treatment of obesity and the complications associated therewith.
|
|
WO1999064038A9 |
Novel multibinding compounds are disclosed. The compounds of the invention comprise from 2-10 ligands covalently connected, each of said ligands being capable of binding to an nAChR receptor, thereby modulating the biological processes/f...
|
|
WO1999064031A9 |
The present invention is directed to multibinding compounds which are beta 2-adrenergic receptor agonists and are therefore useful in the treatment and prevention of respiratory diseases such as asthma, bronchitis, and the like. They are...
|
|
WO/2000/023420A1 |
Compounds represented by formula (I), or salts thereof; a process for the preparation thereof; and somatostatin receptor regulators containing the compounds or salts: wherein A is an optionally substituted aromatic ring; B is an optional...
|
|
WO/2000/023433A1 |
A class of benzopyrans, benzothiopyrans, dihydroquinolines, dihydronaphthalenes, and analogs thereof, is described for use in treating cyclooxygenase-2 mediated disorders. Compounds of particular interest are defined by Formula (I') wher...
|
|
WO1999063933A9 |
Disclosed are multibinding compounds which are agonists, partial agonists, inverse agonists, partial inverse agonist or antagonists of the GABA receptors, which are involved in neurological disorders. The multibinding compounds of this i...
|
|
WO1999064000A9 |
Novel multi-binding compounds (agents) which bind neurokinin receptors are used to treat disorders in mammals that are mediated by the neurokinin receptors, such as Parkinson's disease, Alzheimer's disease, depression, anxiety, inflammat...
|
|
WO/2000/021537A1 |
A number of indenoisoquinolines were prepared and evaluated for cytotoxicity in human cancer cell cultures and for activity vs. topoisomerase I. The two most cytotoxic indenoisoquinolines proved to be $i(cis)-6-ethyl-5, 6, 12, 13-tetrahy...
|
|
WO/2000/020423A1 |
The present invention concerns the compounds of formula (I), the $i(N)-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein Alk is C¿1-6?alkanediyl; n is 1 or 2; X is -O-, ...
|
|
WO/2000/020390A1 |
The invention provides compounds of the formula (I) X-L-X?1¿ wherein X, L, and X?1¿ have any of the meanings defined in the specification; as well as a pharmaceutical composition comprising a compound of formula (I); intermediates and ...
|
|
WO/2000/017165A1 |
Cholesteryl ester transfer protein inhibitors, of the Formula (I), prodrug thereof, or a pharmaceutically acceptable salt of said compound or of said prodrug, pharmaceutical compositions containing such inhibitors and the use of such inh...
|
|
WO/2000/017164A1 |
Cholesteryl ester transfer protein inhibitors of the Formula (I), a prodrug thereof, or a pharmaceutically acceptable salt of said compound or of said prodrug, pharmaceutical compositions containing such inhibitors and the use of such in...
|
|
WO/2000/017167A1 |
The invention relates to compounds of formula (I), their tautomeric and isomeric forms and salts, a method for producing same and their use in medicaments.
|
|
WO/2000/015617A1 |
The invention concerns a compound of formula (I) wherein: A represents a hydrogen atom or hydroxy; B represents a hydrogen atom, a C¿1?-C¿8? alkyl, a C¿2?-C¿8? alkenyl, a fluoro-C¿1?-C¿8? alkyl or a C¿1?-C¿2? perfluoroalkyl, a ph...
|
|
WO1999063983A9 |
Disclosed are novel multi-binding compounds (agents) which bind to PPAR gamma receptors. The compounds of this invention comprise a plurality of ligands each of which can bind to such receptors thereby modulating the biological processes...
|
|
WO1999064043A9 |
Disclosed are multibinding compounds which are muscarinic receptor antagonists. The multibinding compounds of this invention containing from 2 to 10 ligands covalently attached to one or more linkers. Each ligand is, independently of eac...
|
